FLT3 and hepatocellular carcinoma: Sorafenib, a multikinase inhibitor targeting the Raf serine/threonine kinases and the VEGF receptor 1–3 (VEGFR1-3), PDGF receptor (PDGFR)-b, c-Kit, fms-like tyrosine kinase-3 (FLT-3) and p38 tyrosine kinases [3], was the first approved molecule-targeted agent that demonstrated survival benefits in patients with advanced HCC in 2007 [4, 5].